Brind.

Genmab, Amgen, Immunocore, Merck, and Zymeworks are key players in the bispecific antibodies market.

2 reports, 1 independent Updated Jul 29

Gone quiet

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Genmab, Amgen, Immunocore, Merck, and Zymeworks are key players in the bispecific antibodies market.

Who's involved

What this event is mainly about

Genmab Amgen Immunocore Merck Zymeworks

Keep exploring

The entities involved

Genmab
Danish healthcare company
- Genmab, a Danish biotechnology company, granted stock units and warrants via its Board of Directors on September 1, 2026.Thu 21:07
Amgen
American multinational biopharmaceutical company
- Amgen, City of Hope, and the California Community Foundation are involved in a life sciences and bioscience economic summit held in Downtown Los Angeles.Mon 12:08
- Geode Capital Management increased its stake in Amgen stock and filed the disclosure with the SEC.Mon 02:05
Immunocore
UK business

Nothing else this week.
Merck
public company in Indonesia
- Eli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.Sat 17:22
- Merck will share clinical trial results at the American Academy of Ophthalmology (AAO) meeting.Fri 18:13

Related events

Amgen and Merck are currently competing against each other in the market for investor capital.Sep 19

Coverage

Newest first; wire copies grouped

Jul 29GlobeNewswireBispecific Antibodies Market Report 2025- 2035, with Profiles of Akeso Biopharma, Alexion, Amgen, Genmab, Immunocore, Linton Pharm, Merck, OncXerna Therapeutics, Zymeworks, and More The global bispec
Jul 22GlobeNewswireBispecific Antibodies Market Set to Surge to $163.15 Billion by 2032, Driven by a Robust 40.1% CAGR | Roche, Amgen, and Johnson & Johnson at the Forefront: AnalystView Market Insights Bispecific T‑ce